




RealRate

MEDICINAL PRODUCTS 2012

Immunomedics INC
Rank 17 of 41





MEDICINAL PRODUCTS 2012

Immunomedics INC
Rank 17 of 41



The relative strengths and weaknesses of Immunomedics INC are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Immunomedics INC compared to the market average is the variable Stockholders Equity, increasing the Economic Capital Ratio by 78% points. The greatest weakness of Immunomedics INC is the variable Research and Development, reducing the Economic Capital Ratio by 71% points.

The company's Economic Capital Ratio, given in the ranking table, is 183%, being 29% points above the market average of 153%.

Input Variable	Value in 1000 USD
Assets, Current	30,258
Assets, Non-Current	30
General and Administrative Expense	7,944
Goodwill	0
Liabilities, Current	5,548
Liabilities, Non-Current	0
Other Assets	581
Other Compr. Net Income	227
Other Expenses	529
Other Liabilities	0
Other Net Income	480
Other Revenues	18,117
Property, Plant and Equipment, Net	3,456
Research and Development	25,369

Output Variable	Value in 1000 USD
Liabilities	5,548
Assets	34,325
Expenses	33,842
Revenues	18,117
Stockholders Equity	28,776
Net Income	-15,244
Comprehensive Net Income	-15,131
BaseVar	46,270
ECR before LimitedLiability	122%
Economic Capital Ratio	183%